Novoyatleva, Tatyana http://orcid.org/0000-0002-3367-9940
Rai, Nabham
Kojonazarov, Baktybek
Veeroju, Swathi
Ben-Batalla, Isabel
Caruso, Paola http://orcid.org/0000-0002-3071-1917
Shihan, Mazen
Presser, Nadine
Götz, Elsa
Lepper, Carina
Herpel, Sebastian
Manaud, Grégoire
Perros, Frédéric http://orcid.org/0000-0001-7730-2427
Gall, Henning http://orcid.org/0000-0001-7016-7373
Ghofrani, Hossein Ardeschir http://orcid.org/0000-0002-2029-4419
Weissmann, Norbert
Grimminger, Friedrich http://orcid.org/0000-0001-8725-6276
Wharton, John http://orcid.org/0000-0001-8110-2575
Wilkins, Martin http://orcid.org/0000-0003-3926-1171
Upton, Paul D. http://orcid.org/0000-0003-2716-4921
Loges, Sonja
Morrell, Nicholas W. http://orcid.org/0000-0001-5700-9792
Seeger, Werner http://orcid.org/0000-0003-1946-0894
Schermuly, Ralph T. http://orcid.org/0000-0002-5167-6970
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (268555672, 268555672)
Article History
Received: 26 August 2020
Accepted: 5 August 2021
First Online: 24 August 2021
Change Date: 20 January 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42003-022-03045-0
Competing interests
: P.D.U. is a founder of, and scientific advisor to Morphogen-IX Ltd. N.W.M. is a founder and CEO of Morphogen-IX Ltd. P.D.U. and N.W.M. have published US (US10336800) and EU (EP3166628B1) patents entitled: “Therapeutic Use of Bone Morphogenetic Proteins”. All other authors declare no competing interests.